BACKGROUND: The ideal treatment for giant cell tumor of bone (GCTB) is still controversial. The purpose of this study was to evaluate whether curettage was successful in the treatment of GCTB. Intralesional curettage with adjuvant therapies, such as high-speed burring, polymethylmethacrylate, phenol, ethanol, and liquid nitrogen, may be used to reduce the local recurrence rate. However, there is no consensus on the optimal use of curettage, along with fillers and adjuvants, to limit the recurrence rate. METHODS: We performed a systematic review of articles using the terms long bones, GCTB, and treatment. Case reports, reviews, opinion articles, or technique notes were excluded based on the abstract. Twenty-six articles included in this review were then studied to establish the index in suggesting the surgical treatment of GCTB. RESULTS: The patient's gender, their age, the Campanacci grade of their tumor, and the type of surgery they had were not significantly associated with the local recurrence rate. Local recurrences seemed to be associated with the site of the tumor, occurring more frequently in the proximal femur or distal radius. A pathological fracture was not a contraindication for intralesional curettage. Treatment with denosumab did not decrease the local recurrence rate in patients who had been treated with curettage. CONCLUSION: The current literature seems to suggest that the ideal treatment for GCTB is to remove the tumor while preserving as much of the joint as possible. Local recurrent tumors can be treated with curettage to keep the re-recurrence rate within an acceptable limit. The choice for how to treat GCTB in the proximal femur or distal radius requires special attention.
BACKGROUND: The ideal treatment for giant cell tumor of bone (GCTB) is still controversial. The purpose of this study was to evaluate whether curettage was successful in the treatment of GCTB. Intralesional curettage with adjuvant therapies, such as high-speed burring, polymethylmethacrylate, phenol, ethanol, and liquid nitrogen, may be used to reduce the local recurrence rate. However, there is no consensus on the optimal use of curettage, along with fillers and adjuvants, to limit the recurrence rate. METHODS: We performed a systematic review of articles using the terms long bones, GCTB, and treatment. Case reports, reviews, opinion articles, or technique notes were excluded based on the abstract. Twenty-six articles included in this review were then studied to establish the index in suggesting the surgical treatment of GCTB. RESULTS: The patient's gender, their age, the Campanacci grade of their tumor, and the type of surgery they had were not significantly associated with the local recurrence rate. Local recurrences seemed to be associated with the site of the tumor, occurring more frequently in the proximal femur or distal radius. A pathological fracture was not a contraindication for intralesional curettage. Treatment with denosumab did not decrease the local recurrence rate in patients who had been treated with curettage. CONCLUSION: The current literature seems to suggest that the ideal treatment for GCTB is to remove the tumor while preserving as much of the joint as possible. Local recurrent tumors can be treated with curettage to keep the re-recurrence rate within an acceptable limit. The choice for how to treat GCTB in the proximal femur or distal radius requires special attention.
Authors: Richard L McGough; Janie Rutledge; Valerae O Lewis; Patrick P Lin; Alan W Yasko Journal: Clin Orthop Relat Res Date: 2005-09 Impact factor: 4.176
Authors: A E Wijsbek; B L Vazquez-Garcia; R J Grimer; S R Carter; A A Abudu; R M Tillman; L Jeys Journal: Bone Joint J Date: 2014-01 Impact factor: 5.082
Authors: Robert E Turcotte; Jay S Wunder; Marc H Isler; Robert S Bell; Norman Schachar; Bassam A Masri; Guy Moreau; Aileen M Davis Journal: Clin Orthop Relat Res Date: 2002-04 Impact factor: 4.176
Authors: Frank M Klenke; Doris E Wenger; Carrie Y Inwards; Peter S Rose; Franklin H Sim Journal: Clin Orthop Relat Res Date: 2010-09-16 Impact factor: 4.176
Authors: Aarne H Kivioja; Carl Blomqvist; Kalevi Hietaniemi; Clement Trovik; Anders Walloe; Henrik C F Bauer; Peter H Jorgensen; Peter Bergh; Gunnar Follerås Journal: Acta Orthop Date: 2008-02 Impact factor: 3.717
Authors: Maurice Balke; Helmut Ahrens; Arne Streitbuerger; Gabriele Koehler; Winfried Winkelmann; Georg Gosheger; Jendrik Hardes Journal: J Cancer Res Clin Oncol Date: 2008-06-03 Impact factor: 4.553
Authors: Joseph Benevenia; Steven M Rivero; Jeffrey Moore; Joseph A Ippolito; Daniel A Siegerman; Kathleen S Beebe; Francis R Patterson Journal: Clin Orthop Relat Res Date: 2017-03 Impact factor: 4.176
Authors: Lizz van der Heijden; Sjaan Bindt; Maurizio Scorianz; Colin Ng; Max C L H Gibbons; Michiel A J van de Sande; Domenico A Campanacci Journal: Bone Jt Open Date: 2022-07